BridgeBio Pharma (BBIO) Receivables - Other (2019 - 2024)

BridgeBio Pharma has disclosed Receivables - Other across 6 years of filings, most recently posting $200000.0 for Q3 2024.

• Receivables - Other for Q3 2024 came in at $200000.0, down 96.13% year-over-year; the trailing twelve-month figure through Sep 2024 was $200000.0 (down 96.13% YoY), and the FY2023 annual result was $900000.0, down 94.73% from the prior year.
• Receivables - Other came in at $200000.0 for Q3 2024 at BridgeBio Pharma, roughly flat from $200000.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $235.5 million in Q1 2024 to a low of $200000.0 in Q2 2024.
• The 5-year median for Receivables - Other is $7.2 million (2020), against an average of $22.9 million.
• Across the five-year window, Receivables - Other jumped 6956.28% in 2022 and tumbled 96.92% in 2024, its largest moves.
• BridgeBio Pharma's Receivables - Other stood at $8.0 million in 2020, then fell by 21.25% to $6.3 million in 2021, then surged by 171.1% to $17.1 million in 2022, then plunged by 96.49% to $600000.0 in 2023, then slumped by 66.67% to $200000.0 in 2024.
• The last three Receivables - Other figures came in at $200000.0 (Q3 2024), $200000.0 (Q2 2024), and $235.5 million (Q1 2024), per Business Quant data.